Anshul Saigal analyzes the potential returns of PSBs compared to private banks, discusses VIP and Safari s competition, and highlights the impact of US FDA regulations on Indian pharma companies, emphasizing improving business models. On Piramal Pharma and Wockhardt, he points out their business models are improving without recommending a buy.